Trial · NCT04981795
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04981795, Completed, Incyte Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL. Trials, record NCT04981795. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04981795
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
- NCT number
- NCT04981795
- Status
- Completed
- Enrollment
- 102 participants, actual
- Lead sponsor
- Incyte Corporation
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Tafasitamab
- First posted
- 2021-07-29
- Last updated
- 2026-04-27
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Patterns - Safety | 2 Years | Incidence and severity of Treatment-emergent serious AEs (SAEs) and AEs (TEAs) |
| Primary | Treatment Patterns - Effectiveness (a) | 2 Years | Objective response rate (ORR) |
| Primary | Treatment Patterns - Effectiveness (b) | 2 Years | Complete response (CR) rate |
| Primary | Treatment Patterns - Effectiveness (c) | 2 Years | Duration of response (DoR) |
| Primary | Treatment Patterns - Effectiveness (d) | 2 Years | OS |
| Primary | Treatment Patterns - Effectiveness (e) | 2 Years | Progression-free survival (PFS) |
| Primary | Treatment Patterns - Effectiveness (f) | 2 Years | Event-free survival (EFS) |
| Secondary | Physician-reported clinical outcome (a) | 2 Years | Number of treatment lines prior to receiving tafasitamab |
| Secondary | Physician-reported clinical outcome (b) | 2 Years | Distribution of treatment regimens by lines of therapy prior to and subsequent to tafasitamab treatment Duration of tafasitamab treatment (regardless of concomitant treatment with lenalidomide) |
| Secondary | Physician-reported clinical outcome (c) | 2 Years | Duration of combination treatment (i.e., duration of treatment with both tafasitamab and lenalidomide) |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04981795
GET https://conductscience.org/api/trials/v1/NCT04981795/registered